deepull

deepull is a private, pre-revenue diagnostics company tackling the critical unmet need for rapid sepsis diagnosis. Its core technology is a direct-from-blood multiplex PCR assay targeting approximately 95% of sepsis-causing pathogens, with the goal of providing comprehensive pathogen identification and resistance profiling in roughly one hour, compared to the days required by standard blood cultures. If successfully developed and commercialized, this platform could significantly improve antibiotic stewardship and patient outcomes in sepsis, a condition responsible for millions of deaths globally each year.

Direct-from-blood multiplex PCR platform designed to detect total microbial DNA (viable and non-viable organisms) from pathogens causing approximately 95% of sepsis cases, with a goal of one-hour turnaround time.

Competitors include large diagnostics firms (e.g., BioMérieux, Becton Dickinson, Roche) with blood culture and syndromic PCR panels, and other startups developing rapid sepsis tests using various technologies (e.g., T2 Biosystems, Accelerate Diagnostics). deepull's key differentiator is the combination of direct-from-blood analysis, a broad pathogen panel, and a one-hour target turnaround time.